Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abemaciclib - Eli Lilly and Company

Drug Profile

Abemaciclib - Eli Lilly and Company

Alternative Names: Abemaciclib mesylate; Bemaciclib; Bemaciclib mesylate; LY 2835219; Verzenio; Verzenios

Latest Information Update: 20 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Boehringer Ingelheim; Dana-Farber Cancer Institute; Eli Lilly; Eli Lilly and Company; Jules Bordet Institute; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; UCLAs Jonsson Comprehensive Cancer Center; Washington University School of Medicine
  • Class Aminopyridines; Antineoplastics; Benzimidazoles; Fluorinated hydrocarbons; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Liposarcoma; Prostate cancer
  • Phase II Adenocarcinoma; Brain cancer; Cholangiocarcinoma; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Glioblastoma; Mantle-cell lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Urogenital cancer
  • Phase I/II Head and neck cancer
  • Phase I Myelofibrosis
  • No development reported Cancer; Renal cell carcinoma

Most Recent Events

  • 14 May 2024 Eli Lilly and Company plans a phase II trial for Glioma (Adjunctive treatment; In neonates; In infants; In children; In adolescents; In adults; Late-stage disease, first-line therapy) in USA (PO/IV) in June 2024 (NCT06413706)
  • 21 Feb 2024 Discontinued - Phase-II for Prostate cancer (Second-line therapy or greater, Metastatic disease, Hormone refractory) in Spain, USA and Australia (PO)
  • 21 Feb 2024 Discontinued - Phase-III for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in China Denmark Germany Japan Netherlands Puerto Rico Romania South Korea Spain USA United Kingdom France Spain USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top